Related Immunotherapy and Progress of Cervical Cancer

doi:10.12280/gjfckx.20210116

Abstract

Abstract:

Cervical cancer is the most common gynecological malignant tumor, which is a serious threat to women′s health. High-risk human papillomavirus (HPV) persistent infection is the main risk factor of the cervical cancer. In recent years, HPV vaccine has achieved favorable results in the prevention of cervical cancer. Immunotherapy has also become a new pattern of treatment of cervical cancer, especially for patients with poor effect of surgery, radiotherapy and chemotherapy, postoperative metastasis and late recurrence. The strategies of immunotherapy mainly include immune checkpoint inhibitors, vaccine therapy, dendritic cell immunotherapy and adoptive cellular immunotherapy. At present, the related immunotherapy has achieved good results in the treatment of cervical cancer and its precancerous lesions. This article will describe the progress of immunotherapy in cervical cancer, and look forward to the future research direction, so as to provide a basis for clinical treatment and fundamental research of cervical cancer.

Key words: Uterine cervical neoplasms, Immunotherapy, Papillomaviridae, Papillomavirus vaccines, Therapy

YIN Bo, DING Jian-yi, YANG Mei-qin, HAN Ling-fei. Related Immunotherapy and Progress of Cervical Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(6): 628-633.

References 29

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019,69(1):7-34. doi: 10.3322/caac.21551. doi: 10.3322/caac.21551
[2]	Lee SJ, Yang A, Wu TC, et al. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research[J]. J Gynecol Oncol, 2016,27(5):e51. doi: 10.3802/jgo.2016.27.e51. doi: 10.3802/jgo.2016.27.e51
[3]	Chan CK, Aimagambetova G, Ukybassova T, et al. Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives[J]. J Oncol, 2019,2019:3257939. doi: 10.1155/2019/3257939. doi: 10.1155/2019/3257939
[4]	Mühr L, Eklund C, Dillner J. Towards quality and order in human papillomavirus research[J]. Virology, 2018,519:74-76. doi: 10.1016/j.virol.2018.04.003. doi: 10.1016/j.virol.2018.04.003
[5]	Allouch S, Malki A, Allouch A, et al. High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions[J]. Front Oncol, 2020,10:914. doi: 10.3389/fonc.2020.00914. doi: 10.3389/fonc.2020.00914
[6]	Menéndez-Menéndez J, Hermida-Prado F, Granda-Díaz R, et al. Deciphering the Molecular Basis of Melatonin Protective Effects on Breast Cells Treated with Doxorubicin: TWIST1 a Transcription Factor Involved in EMT and Metastasis, a Novel Target of Melatonin[J]. Cancers (Basel), 2019,11(7) doi: 10.3390/cancers11071011. doi: 10.3390/cancers11071011
[7]	Li X, Wang R, Fan P, et al. A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer[J]. Front Oncol, 2019,9:1066. doi: 10.3389/fonc.2019.01066. doi: 10.3389/fonc.2019.01066
[8]	Cheng MA, Farmer E, Huang C, et al. Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases[J]. Hum Gene Ther, 2018,29(9):971-996. doi: 10.1089/hum.2017.197. doi: 10.1089/hum.2017.197 pmid: 29316817
[9]	Menderes G, Black J, Schwab CL, et al. Immunotherapy and targeted therapy for cervical cancer: an update[J]. Expert Rev Anticancer The, 2016,16(1):83-98. doi: 10.1586/14737140.2016.1121108. doi: 10.1586/14737140.2016.1121108
[10]	Chabeda A, Yanez R, Lamprecht R, et al. Therapeutic vaccines for high-risk HPV-associated diseases[J]. Papillomavirus Res, 2018,5:46-58. doi: 10.1016/j.pvr.2017.12.006. doi: S2405-8521(17)30057-5 pmid: 29277575
[11]	Vonsky M, Shabaeva M, Runov A, et al. Carcinogenesis Associated with Human Papillomavirus Infection. Mechanisms and Potential for Immunotherapy[J]. Biochemistry (Mosc), 2019,84(7):782-799. doi: 10.1134/S0006297919070095. doi: 10.1134/S0006297919070095
[12]	Peter M, Kühnel F. Oncolytic Adenovirus in Cancer Immunotherapy[J]. Cancers (Basel), 2020,12(11):3354. doi: 10.3390/cancers12113354. doi: 10.3390/cancers12113354
[13]	Hasan Y, Furtado L, Tergas A, et al. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer[J]. Int J Radiat Oncol Biol Phys, 2020,107(3):487-498. doi: 10.1016/j.ijrobp.2020.02.031. doi: 10.1016/j.ijrobp.2020.02.031
[14]	Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors[J]. Cochrane Database Syst Rev, 2018,5(5):CD009069. doi: 10.1002/14651858.CD009069.pub3. doi: 10.1002/14651858.CD009069.pub3
[15]	Østergård S, Vorbeck CS, Meinert M. Vulvar intraepithelial neoplasia[J]. Ugeskr Laeger, 2018,180(20):V12170931.
[16]	Kim TJ, Jin HT, Hur SY, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients[J]. Nat Commun, 2014,5:5317. doi: 10.1038/ncomms6317. doi: 10.1038/ncomms6317
[17]	Çuburu N, Khan S, Thompson CD, et al. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8(+) T cell responses against HPV16 oncoproteins[J]. Int J Cancer, 2018,142(7):1467-1479. doi: 10.1002/ijc.31166. doi: 10.1002/ijc.31166
[18]	Kim TW, Hung CF, Juang J, et al. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death[J]. Gene Ther, 2004,11(3):336-342. doi: 10.1038/sj.gt.3302164. doi: 10.1038/sj.gt.3302164 pmid: 14737094
[19]	Fakhr E, Modic Ž, Cid-Arregui A. Recent developments in immunotherapy of cancers caused by human papillomaviruses[J]. Immunology, 2021,163(1):33-45. doi: 10.1111/imm.13285. doi: 10.1111/imm.13285
[20]	Schetters S, Jong W, Horrevorts SK, et al. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8(+) T cells[J]. Acta Biomater, 2019,91:248-257. doi: 10.1016/j.actbio.2019.04.033. doi: S1742-7061(19)30276-4 pmid: 31003032
[21]	Santin AD, Bellone S, Palmieri M, et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities[J]. Gynecol Oncol, 2006,100(3):469-478. doi: 10.1016/j.ygyno.2005.09.040. doi: 10.1016/j.ygyno.2005.09.040
[22]	Aipire A, Li J, Yuan P, et al. Glycyrrhiza uralensis water extract enhances dendritic cell maturation and antitumor efficacy of HPV dendritic cell-based vaccine[J]. Sci Rep, 2017,7:43796. doi: 10.1038/srep43796. doi: 10.1038/srep43796 pmid: 28272545
[23]	Zsiros E, Tsuji T, Odunsi K. Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer[J]. J Clin Oncol, 2015,33(14):1521-1522. doi: 10.1200/JCO.2014.60.6566. doi: 10.1200/JCO.2014.60.6566 pmid: 25847926
[24]	Jin BY, Campbell TE, Draper LM, et al. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model[J]. JCI Insight, 2018,3(8):e99488. doi: 10.1172/jci.insight.99488. doi: 10.1172/jci.insight.99488
[25]	Singh N, Shi J, June CH, et al. Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer[J]. Curr Hematol Malig Rep, 2017,12(6):522-529. doi: 10.1007/s11899-017-0417-7. doi: 10.1007/s11899-017-0417-7
[26]	Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine[J]. Nat Rev Immunol, 2020,20(5):321-334. doi: 10.1038/s41577-019-0269-6. doi: 10.1038/s41577-019-0269-6
[27]	Zhuo M, Chi Y, Wang Z. The adverse events associated with combination immunotherapy in cancers: Challenges and chances[J]. Asia Pac J Clin Oncol, 2020,16(5):e154-e159. doi: 10.1111/ajco.13365. doi: 10.1111/ajco.13365
[28]	Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy[J]. Nat Commun, 2019,10(1):5408. doi: 10.1038/s41467-019-13368-y. doi: 10.1038/s41467-019-13368-y
[29]	Lei X, Lei Y, Li JK, et al. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy[J]. Cancer Lett, 2020,470:126-133. doi: 10.1016/j.canlet.2019.11.009. doi: S0304-3835(19)30564-6 pmid: 31730903